论文部分内容阅读
Objective: The aim of this study was to investigate the early outcome of the nedaplatin and megestrol combine chemoradiotherapy to the advanced cervical cancer. Methods: Forty-two cases with cervical cancer (FIGO IIb to IVa) were divided randomly into two groups, radiotherapy alone (RT group: 21 cases) and radiation combines chemotherapy (nedaplatin and megestrol) (RT + C group: 21 cases). There was no difference of radiotherapy between the two groups, the RT + C group accepted nedaplatin injection during the radiation weekly, according to 30 mg/m2 ,these regimen were given for 4-5 weeks. This group was received an oral medicine megestrol 160 mg every day during the treatment. Results: The RT + C group: the complete remission rate was 80.9% (17/21), the partial remission rate was 19.1% (4/21), the effective rate was 100%. The RT group: the complete remission rate was 38.1% (8/21) and partial remission rate was 32.9% (9/21), the effective rate was 81.0%. The total effective rate and complete remission rate of RT + C group were higher than RT group. There was significant difference between the two groups. The 1-year survival rates respectively were 100% (21/21) in RT + C group, 80.9% (17/21) in RT group. There was statistically significant difference between the two groups (χ2 = 4.42 > 3.84, P < 0.05). Conclusion: The nedaplatin and megestrol combine chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and the adverse effects was raised, but that can be endured.